The U.S. Food and Drug Administration approved Inlyta to treat patients with advanced kidney cancer who have not responded to another drug for this type of cancer. The group said Renal cell carcinoma is a type of kidney cancer that starts in the lining of very small tubes in the kidney. "This is the seventh drug that has been approved for the treatment of metastatic...
The U.S. Food and Drug Administration approved Inlyta to treat patients with advanced kidney cancer who have not responded to another drug for this type of cancer. The group said Renal cell carcinoma is a type of kidney cancer that starts in the lining of very small tubes in the kidney. "This is the seventh drug that has been approved for the treatment of metastatic...
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute and breakthrough pain, reported that the two remaining items required by the FDA prior to the initiation of the Phase 3 clinical program for ARX-01, specifically software verification and validation...
Is the Scottish Government doing enough to alert the population to the dangers of vitamin D deficiency? Yesterday Chief Medical Officer Sir Harry Burns and his opposite numbers from elsewhere in the UK reiterated warnings to health professionals about the importance of ensuring patients at risk of a deficiency are getting enough vitamin D. If necessary,...
Aeras announced that the National Institute of Allergy and Infectious Diseases, part of the United States National Institutes of Health, has joined as a partner for a Phase II proof-of-concept clinical trial of a tuberculosis vaccine candidate jointly developed by Aeras and Dutch biopharmaceutical company Crucell. "NIAID's involvement in this important...
As rector of Imperial College, the former GlaxoSmithKline chairman Sir Richard Sykes used to say that financial services had a great deal to learn from pharmaceuticals- especially how they should adopt drug companies' approach to product safety and efficacy. Current Glaxo boss Andrew Witty has been at the vanguard of the industry's moves, and is likely to be...
